

PE anti-mouse CD3 Antibody

Catalog# / Size	100205 / 50 µg 100206 / 200 µg
Clone	17A2
Regulatory Status	RUO
Other Names	T cell antigen receptor complex, T3
Isotype	Rat IgG2b, κ
Description	CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	γδTCR-positive T-T hybridoma D1
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported application (for relevant formats) include: spatial biology (IBEX) ^{1,2} .
Application References	1. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed 2. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed
(PubMed link indicates BioLegend citation)	
Product Citations	1. Pedraza-Zamora C, <i>et al.</i> 2017. <i>Parasite Immunol.</i> 10.1111/pim.12420. PubMed 2. Xu C, <i>et al.</i> 2017. <i>Biochemical and Biophysical Research Communications.</i> 10.1016/j.bbrc.2017.05.071. PubMed 3. Ushijima M, <i>et al.</i> 2018. <i>Front Immunol.</i> 9:243. PubMed 4. Xiang W, <i>et al.</i> 2018. <i>Nat Commun.</i> 9:2574. PubMed 5. Sun J <i>et al.</i> 2018. <i>Cell stem cell.</i> 23(3):355-369. PubMed 6. Huang L, <i>et al.</i> 2018. <i>Exp Neurol.</i> 300:41. PubMed 7. Chan WY, <i>et al.</i> 2019. <i>Infect Immun.</i> 87:. PubMed 8. Pedraza-Zamora CP, <i>et al.</i> 2017. <i>Parasite Immunol.</i> 39:4. PubMed 9. Stivala S, <i>et al.</i> 2019. <i>J Clin Invest.</i> 130:1596. PubMed 10. Doonan J, <i>et al.</i> 2019. <i>Nat Commun.</i> 10:1554. PubMed

11. Halpern KB, *et al.* 2018. *Nat Biotechnol.* 36:962. [PubMed](#)
12. Kim JH, *et al.* 2019. *Mol Med.* 25:33. [PubMed](#)
13. Shen S, *et al.* 2018. *Pain Med.* 19:686. [PubMed](#)
14. Mariani SA, *et al.* 2019. *Immunity.* 50:1439. [PubMed](#)
15. Baryawno N *et al.* 2019. *Cell.* 177(7):1915-1932. [PubMed](#)
16. Baptista AP *et al.* 2019. *Immunity.* 50(5):1188-1201. [PubMed](#)
17. Delgado-Benito V *et al.* 2018. *Molecular cell.* 72(4):636-649. [PubMed](#)
18. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134. [PubMed](#)
19. Gundra UM, *et al.* 2017. *Nat Immunol.* 1.195833333. [PubMed](#)
20. Mishra BB, *et al.* 2017. *Nat Microbiol.* 2:17072. [PubMed](#)
21. Periasamy S, *et al.* 2017. *Nat Commun.* 8:15564. [PubMed](#)
22. Ma C, *et al.* 2018. *Science.* 360:eaan5931. [PubMed](#)
23. Lin H, *et al.* 2019. *Infect Immun.* 87:e00055-19. [PubMed](#)
24. Hidalgo San Jose L, *et al.* 2020. *Cell Rep.* 30:69. [PubMed](#)
25. Biram A, *et al.* 2020. *Cell Rep.* 30:1910. [PubMed](#)
26. Zou D, *et al.* 2020. *EBioMedicine.* 52:102652. [PubMed](#)
27. Crowe J, *et al.* 2020. *PLoS Pathog.* 16:e1008391. [PubMed](#)
28. Lutzmann M, *et al.* 2019. *Cell Rep.* 28:2851. [PubMed](#)
29. Tsuchiya N, *et al.* 2020. *Cell Reports.* 29(1):162-175.e9. [PubMed](#)
30. Vannini N, *et al.* 2019. *Cell Stem Cell.* 24:405. [PubMed](#)
31. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
32. Domingos-Pereira S, *et al.* 2019. *Cancer Immunol Res.* 7:621. [PubMed](#)
33. Deng M, *et al.* 2020. *Nat Commun.* 11:2193. [PubMed](#)
34. Chauveau A, *et al.* 2020. *Immunity.* 52:794. [PubMed](#)
35. Frodermann V, *et al.* 2019. *Nat Med.* 25:1761. [PubMed](#)
36. Ding Y, *et al.* 2020. *Evid Based Complement Alternat Med.* 2020:9521073. [PubMed](#)
37. Winchell CG, *et al.* 2020. *Front Immunol.* 1.077083333. [PubMed](#)
38. Yao C, *et al.* 2018. *Autophagy.* 1.854861111. [PubMed](#)
39. O'Connor T, *et al.* 2020. *Cancer Cell.* 36(3):250-267. [PubMed](#)
40. Uluçkan ö, *et al.* 2020. *Cell Reports.* 29(4):844-859.e3. [PubMed](#)
41. Zhang T, *et al.* 2020. *Cell.* 180(6):1115-1129. [PubMed](#)
42. Kunimura K, *et al.* 2020. *Cell Reports.* 29(9):2823-2834.e7. [PubMed](#)
43. Paul S, *et al.* 2018. *Appl Microbiol Biotechnol.* 102:8895. [PubMed](#)
44. Fathman J, *et al.* 2010. *Proc Natl Acad Sci U S A.* 107:3663. [PubMed](#)
45. Bedi B, *et al.* 2012. *Proc Natl Acad Sci U S A.* 109:275. [PubMed](#)
46. Hsieh Y, *et al.* 2014. *Infect Immun.* 82:2087. [PubMed](#)
47. Gazit R, *et al.* 2014. *J Exp Med.* 211:1315. [PubMed](#)
48. Schneider A, *et al.* 2014. *J Leukoc Biol.* 96:857. [PubMed](#)
49. Rozanski C, *et al.* 2015. *J Immunol.* 194:4717. [PubMed](#)
50. Chen Y, *et al.* 2015. *PLoS One.* 10: 0135217. [PubMed](#)
51. Yu H, *et al.* 2015. *PLoS One.* 10: 0143001. [PubMed](#)
52. Stutchfield B, *et al.* 2015. *Gastroenterology.* 149: 1896-1909.e14. [PubMed](#)
53. Zuchtriegel G, *et al.* 2016. *PLoS Biol.* 14: 1002459. [PubMed](#)
54. Reboldi A, *et al.* 2016. *Sci Transl Med.* 352: aaf4822. [PubMed](#)
55. Schmidt D, *et al.* 2016. *PLoS One.* 11: 0159059. [PubMed](#)
56. Vannini N, *et al.* 2016. *Nat Commun.* 7:13125. [PubMed](#)
57. Yamamura K, *et al.* 2017. *Nat Commun.* 8:13946. [PubMed](#)
58. Hayashi K, *et al.* 2020. *Nat Commun.* 4.832638889. [PubMed](#)
59. Liang W, *et al.* 2020. *Nat Commun.* 4.563888889. [PubMed](#)
60. Fang H, *et al.* 2020. *Nat Commun.* 4.661805556. [PubMed](#)
61. Xiang W, *et al.* 2020. *Signal Transduct Target Ther.* 0.374305556. [PubMed](#)
62. Lewandowski JP, *et al.* 2020. *Genome Biol.* 1.039583333. [PubMed](#)
63. Zhou T, *et al.* 2021. *Bioact Mater.* 0.734027778. [PubMed](#)
64. Cai Z, *et al.* 2020. *Cell Rep.* 31:107816. [PubMed](#)
65. Zhang D, *et al.* 2020. *Signal Transduct Target Ther.* 5:24. [PubMed](#)
66. He C, *et al.* 2020. *Clin Transl Med.* 10:e39. [PubMed](#)
67. Guo S, *et al.* 2021. *Frontiers in Immunology.* 11:614667. [PubMed](#)
68. Tummers B, *et al.* 2020. *Immunity.* 52(6):994-1006.e8. [PubMed](#)
69. Li Y, *et al.* 2020. *Cell Stem Cell.* 27(5):732-747.e7. [PubMed](#)
70. Lu C, *et al.* 2020. *Cancer Cell.* 39(1):96-108.e6. [PubMed](#)
71. Koren N, *et al.* 2021. *Cell Host Microbe.* 29(2):197-209.e5. [PubMed](#)
72. Chen R, *et al.* 2021. *Cell Reports.* 34(7):108751. [PubMed](#)
73. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
74. Gonalves S, *et al.* 2021. *Cell Reports.* 34(11):108860. [PubMed](#)

RRID

AB_312662 (BioLegend Cat. No. 100205)
 AB_312663 (BioLegend Cat. No. 100206)

Antigen Details

Structure	Ig superfamily, CD3/TCR, 20 kD
Distribution	Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function	Antigen recognition, TCR signal transduction, T cell activation

Ligand/Receptor Peptide antigen/MHC-complex

Antigen References

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. *Annu. Rev. Biochem.* 59:475.
3. Weiss A, *et al.* 1994. *Cell* 76:263.

Gene ID [12502](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

FITC anti-mouse CD3, PE anti-mouse CD3, Purified anti-mouse CD3, Alexa Fluor® 647 anti-mouse CD3, Alexa Fluor® 488 anti-mouse CD3, Pacific Blue™ anti-mouse CD3, Alexa Fluor® 700 anti-mouse CD3, PerCP/Cyanine5.5 anti-mouse CD3, PE/Cyanine7 anti-mouse CD3, APC/Cyanine7 anti-mouse CD3, Brilliant Violet 421™ anti-mouse CD3, Brilliant Violet 570™ anti-mouse CD3, Brilliant Violet 650™ anti-mouse CD3, Brilliant Violet 785™ anti-mouse CD3, Brilliant Violet 510™ anti-mouse CD3, APC anti-mouse CD3, Ultra-LEAF™ Purified anti-mouse CD3, Brilliant Violet 605™ anti-mouse CD3, Alexa Fluor® 594 anti-mouse CD3, Brilliant Violet 711™ anti-mouse CD3, Biotin anti-mouse CD3, PE/Dazzle™ 594 anti-mouse CD3, APC/Fire™ 750 anti-mouse CD3, Brilliant Violet 750™ anti-mouse CD3, TotalSeq™-A0182 anti-mouse CD3, TotalSeq™-B0182 anti-mouse CD3, Spark Blue™ 550 anti-mouse CD3, Spark NIR™ 685 anti-mouse CD3, TotalSeq™-C0182 anti-mouse CD3, APC/Fire™ 810 anti-mouse CD3, PE/Fire™ 640 anti-mouse CD3, Spark YG™ 570 anti-mouse CD3, PE/Fire™ 700 anti-mouse CD3, PE/Cyanine5 anti-mouse CD3, Spark Blue™ 574 anti-mouse CD3 Antibody, Spark Violet™ 423 anti-mouse CD3, PE/Fire™ 810 anti-mouse CD3, Spark Red™ 718 anti-mouse CD3

Product Data



C57BL/6 mouse splenocytes stained with 17A2 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587